Skip to main content
Clinical Trials/ACTRN12613000762752
ACTRN12613000762752
Active, Not Recruiting
N/A

All cause and cardiovascular mortality among Australian adult dialysis patients prescribed sevelamer hydrochloride and lanthanum carbonate compared with calcium-based phosphate binders.

A/Prof Grahame Elder0 sites15,000 target enrollmentJuly 9, 2013

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
A/Prof Grahame Elder
Enrollment
15000
Status
Active, Not Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 9, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
A/Prof Grahame Elder

Eligibility Criteria

Inclusion Criteria

  • Australian dialysis patients aged over 18 years of age and registered in ANZDATA registry will be included in the study.

Exclusion Criteria

  • New Zealand patients and patients aged less than 18 years of age in ANZDATA registry will be excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Mortality and risk factors for cardiovascular and non-cardiovascular disease in Japanese with impaired glucose metabolism
JPRN-UMIN000036648Hiroshima Atomic Bomb Casualty Council19,248
Active, Not Recruiting
Phase 1
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 16.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-003946-34-CZVIVUS, Inc.16,000
Active, Not Recruiting
Phase 1
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 14.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-003946-34-SKVIVUS, Inc.16,000
Active, Not Recruiting
N/A
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 16.0Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2012-003946-34-GBVIVUS, Inc.16,000
Completed
N/A
Risk factors for mortality and cardiovascular diseases in older adults in a primaray care setting – longitudinal analysis of the getABI-studyRisk factors for mortality and cardiovascular diseasesI70.20
DRKS00011624Ruhr-Universität Bochum6,880